文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA-11 PET/CT 与多参数 MRI 检测前列腺内放射性复发前列腺癌的诊断性能比较

Diagnostic Performance of 68Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer.
PubMed 文献 · J Nucl Med · 2024-03-01

单中心回顾性研究纳入35例放疗后生化失败患者(70个半腺),比较68Ga-PSMA-11 PET/CT与多参数MRI检测前列腺内复发的诊断准确性。PET/CT灵敏度0.89与MRI的0.72无显著差异(P=0.1),两者联合灵敏度0.98显著高于MRI单用(P=0.003)。MRI漏诊的12处癌中11处被PET/CT检出。

要点

  • PET/CT灵敏度0.89与mpMRI的0.72无显著差异(P=0.1),阴性预测值0.79对0.59亦无显著差异(P=0.07)。
  • PET/CT联合mpMRI灵敏度0.98、阴性预测值0.93,均显著高于mpMRI单用(P=0.003和P<0.001)。
  • mpMRI漏诊43处癌中的12处(28%),其中11处(92%)被PET/CT检出。

核心结论

  • 对于检测前列腺内放射性复发,68Ga-PSMA-11 PET/CT具有高灵敏度,与mpMRI无显著差异。
  • 68Ga-PSMA-11 PET/CT与mpMRI联合使用时,灵敏度和阴性预测值均显著高于mpMRI单用。
  • 68Ga-PSMA-11 PET/CT可能因此成为诊断局限性放射性复发的有用工具。

研究设计与样本

  • 单中心回顾性研究,纳入2016年至2022年间因放射性复发接受检查的一系列患者。
  • 所有患者均接受68Ga-PSMA-11 PET/CT、mpMRI和前列腺活检。
  • PET/CT图像由2名对其它影像和临床数据设盲的专家读者独立判读。
  • 共纳入35名男性(70个半腺),活检证实43个半腺(61%)存在癌症。
  • 诊断准确性分析在半腺水平使用聚类自举法进行。

主要发现

  • PET/CT灵敏度0.89(95%CI 0.78-0.98),阴性预测值0.79(95%CI 0.62-0.95)。
  • MRI灵敏度0.72(95%CI 0.61-0.83),阴性预测值0.59(95%CI 0.41-0.75)。
  • PET/CT与MRI的灵敏度差异P=0.1,阴性预测值差异P=0.07,均无统计学显著差异。
  • PET/CT联合MRI灵敏度0.98(95%CI 0.92-1.00),阴性预测值0.93(95%CI 0.75-1.00)。
  • 联合方案与MRI单用比较,灵敏度P=0.003,阴性预测值P<0.001,均显著更高;特异度和阳性预测值无显著差异。

关键数值与推荐

  • 欧洲指南推荐对放疗后生化失败的前列腺癌男性使用68Ga-PSMA-11 PET/CT和mpMRI重新成像。
  • 主要结局为PET/CT对比mpMRI、以及PET/CT联合mpMRI对比mpMRI单用的诊断准确性。
  • 次要结局为mpMRI漏诊但被PET/CT检出的癌症比例。

临床怎么用

  • 欧洲指南推荐对放疗后生化失败的前列腺癌男性使用68Ga-PSMA-11 PET/CT和mpMRI重新成像。
  • 作者认为68Ga-PSMA-11 PET/CT可能是诊断局限性放射性复发的有用工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For men with prostate cancer who develop biochemical failure after radiotherapy, European guidelines recommend reimaging with 68Ga-PSMA-11 PET/CT and multiparametric MRI (mpMRI). However, the accuracy of 68Ga-PSMA-11 PET/CT for detecting intraprostatic recurrences is unclear, both with and without mpMRI. Methods: A single-center retrospective study of a series of patients investigated for radiorecurrence between 2016 and 2022 is described. All patients underwent 68Ga-PSMA-11 PET/CT, mpMRI, and prostate biopsy. PET/CT images were interpreted independently by 2 expert readers masked to other imaging and clinical data. The primary outcome was the diagnostic accuracy of PET/CT versus mpMRI and of PET/CT with mpMRI together versus mpMRI alone. The secondary outcome was the proportion of cancers missed by mpMRI but detected by PET/CT. Diagnostic accuracy analysis was performed at the prostate hemigland level using cluster bootstrapping. Results: Thirty-five men (70 hemiglands) were included. Cancer was confirmed by biopsy in 43 of 70 hemiglands (61%). PET/CT sensitivity and negative predictive values (NPVs) were 0.89 (95% CI, 0.78-0.98) and 0.79 (95% CI, 0.62-0.95), respectively, which were not significantly different from results by MRI (sensitivity of 0.72; 95% CI, 0.61-0.83; P = 0.1) (NPV of 0.59; 95% CI, 0.41-0.75; P = 0.07). Specificity and positive predictive values were not significantly different. When PET/CT and MRI were used together, the sensitivity was 0.98 (95% CI, 0.92-1.00) and NPV was 0.93 (95% CI, 0.75-1.00), both significantly higher than MRI alone (P = 0.003 and P < 0.001, respectively). Specificity and positive predictive values remained not significantly different. MRI missed 12 of 43 cancers (28%; 95% CI, 17%-43%), of which 11 of 12 (92%; 95% CI, 62%-100%) were detected by PET/CT. Conclusion: For detecting intraprostatic radiorecurrence, 68Ga-PSMA-11 PET/CT has high sensitivity that is not significantly different from mpMRI. When 68Ga-PSMA-11 PET/CT and mpMRI were used together, the results conferred a significantly greater sensitivity and NPV than with mpMRI alone. 68Ga-PSMA-11 PET/CT may therefore be a useful tool in the diagnosis of localized radiorecurrence.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Light A, Lazic S, Houghton K, et al. Diagnostic Performance of 68Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer. J Nucl Med. 2024. PMID: 38212074. doi:10.2967/jnumed.123.266527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。